Bioequivalence of IR vs MR tablet [Design Issues]
One drug has been approved as IR tablet given 100 mg bid (total dose 200 mg). We want to make one ER formulation of 230 mg which can be given once daily. I need help in following issues
1. What should be the design?
2. Which PK parameter I should be looking at?
3. Should I do fasting or fed study?
4. Should I targeting BE in Cmax or AUC?
Please give me some reading material or link to any post wherein this had been already discussed
Thanks in advance
Edit: Category changed; see also this post #1. [Helmut]
1. What should be the design?
2. Which PK parameter I should be looking at?
3. Should I do fasting or fed study?
4. Should I targeting BE in Cmax or AUC?
Please give me some reading material or link to any post wherein this had been already discussed
Thanks in advance
Edit: Category changed; see also this post #1. [Helmut]
Complete thread:
- Bioequivalence of IR vs MR tablet - heritage, 2018-05-05 06:25 [Design Issues]
- Consider 505(b)(2) Pathway - bebac_fan, 2018-05-05 17:08
- Pathway for Softgel vs Tablet Comparison - Obinoscopy, 2018-05-15 19:04
- Pathway for Softgel vs Tablet Comparison - jag009, 2018-05-18 16:33
- Pathway for Softgel vs Tablet Comparison - Obinoscopy, 2018-05-15 19:04
- Consider 505(b)(2) Pathway - bebac_fan, 2018-05-05 17:08